Precious Nwodo

Ms. Precious Nwodo


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2026 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
DDD.N. Davidyuk
D.N. Davidyuk
SSSvetlana Samoylova
Svetlana Samoylova
TDTatiana Demura
Tatiana Demura
IRI.V. Reshetov
I.V. Reshetov
ZXZ. Xu
Z. Xu
PNPrecious Nwodo
Precious Nwodo
Squamous cell carcinoma of the tongue and oropharynx is characterized by significant clinical and biological heterogeneity, highlighting the need for reliable prognostic and predictive biomarkers. This review analyzes current evidence regarding the significance of programmed death-ligand 1 (PD-L1) expression and immune microenvironment characteristics in these malignancies. PD-L1 has been shown to play a central role in tumor immune evasion; however, its prognostic value remains controversial and appears to depend on human papillomavirus (HPV) status, tumor immune contexture, and methodological approaches used for assessment. More consistent associations with clinical outcomes have been demonstrated for immune infiltration parameters, including high densities of CD8+ T lymphocytes, abundant tumor-infiltrating lymphocytes, and a favorable balance between effector and regulatory immune cells. The combined assessment of PD-L1 expression, immune microenvironment features, and HPV status may improve patient stratification and facilitate personalized treatment strategies. Further studies are required to standardize PD-L1 evaluation methods and to develop integrated prognostic models incorporating molecular and immunological biomarkers.

13 March 2026 in South Russian Journal of Cancer
Verified
Journal Article
Open access
PDF file
HYHan Yuyao
Han Yuyao
SSSvetlana Samoylova
Svetlana Samoylova
IRI. V. Reshetov
I. V. Reshetov
XSXu Shijun
Xu Shijun
DDD. N. Davidyuk
D. N. Davidyuk
ЯCЯн Cиньи
Ян Cиньи
Прогностическая значимость исследований CD44 и CK19 при плоскоклеточном раке головы и шеи

19 October 2026 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
Solomon Oloche OnojaSolomon Oloche Onoja
Solomon Oloche Onoja
ESEsther Ene Solomon
Esther Ene Solomon
FKFemi Ezekiel Komolafe
Femi Ezekiel Komolafe
OAOmara Geoffrey Abacha
Omara Geoffrey Abacha
AOAmechi Junior Odeku
Amechi Junior Odeku
Abah Moses Owoicho OwoichoAbah Moses Owoicho Owoicho
Abah Moses Owoicho Owoicho

12 January 2026 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
Yvan Sinclair NGAHA TCHAWEYvan Sinclair NGAHA TCHAWE
Yvan Sinclair NGAHA TCHAWE
Essogmo Freddy EladEssogmo Freddy Elad
Essogmo Freddy Elad
IUIkenna Kingsley Uchendu
Ikenna Kingsley Uchendu
Abah Moses Owoicho OwoichoAbah Moses Owoicho Owoicho
Abah Moses Owoicho Owoicho
AZAngelina V. Zhilenkova
Angelina V. Zhilenkova
Marina I. SekachevaMarina I. Sekacheva
Marina I. Sekacheva
Background: Lung cancer remains the leading cause of cancer mortality world-wide, underscoring the need for non-invasive early diagnostic tools. IP-10, a cytokine involved in inflammation and angiogenesis, is a promising candidate. The present study aims to assess the relevance of IP-10 in lung cancer early diagnosis. Methods: In this cross-sectional study, we measured serum IP-10 levels using Luminex assays in 52 treatment-naïve lung cancer patients without comorbidities and 14 healthy controls. Based on the non-normal distribution of data, group comparisons were performed using Wil-coxon rank-sum tests. Multivariate linear regression was used to adjust for cofounders. Results: IP-10 levels were significantly elevated in lung cancer patients compared to healthy controls (median: 189.69 pg/mL vs. 108.78 pg/mL, p = 0.001). This significance persisted in the early-stage subgroup (stages 0-IIA; median: 192.49 pg/mL vs. 108.78 pg/mL, p = 0.001), even after multivariate adjustment (p = 0.018). Levels peaked in evolved early-stage disease (median: 241.42 pg/mL) before declining in advanced stages, while remaining elevated above controls. Discussion: The rise in IP-10 levels in early-stage lung cancer patients emphasizes its potential to serve as an early diagnostic biomarker. Meanwhile, the peak-and-decline pattern during phases of disease is consistent with its postulated dual role in early antitumor immunity and later tumor promotion. Conclusion: IP-10 can potentially be used as a supplemental serum biomarker for early lung cancer diagnosis. This finding calls for additional validation in bigger, multi-center cohorts to define diagnostic thresholds and investigate their incorporation into multi-marker panels.